Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
Background. Cytarabine use during pregnancy carries a 5–7% risk of neonatal cytopenia. We report two cases of fetal myelosuppression following high-dose cytarabine administration for acute myeloid leukemia (AML). Case 1. A 36-year-old G9P6 diagnosed with AML at 21 weeks was monitored for fetal anemi...
Saved in:
Main Authors: | Jessica Parrott, Marium Holland |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2017/5175629 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
by: Brandi Anders, et al.
Published: (2017-01-01) -
Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness
by: Linu A. Jacob, et al.
Published: (2015-01-01) -
Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin
by: Jinhua Piao, et al.
Published: (2022-01-01) -
Case report: Dysphonia associated with high-dose cytarabine therapy
by: Ling Ma, et al.
Published: (2025-01-01) -
Prolonged Myelosuppression due to Progressive Bone Marrow Fibrosis in a Patient with Acute Promyelocytic Leukemia
by: Yuta Inagawa, et al.
Published: (2019-01-01)